ProNAi Therapeutics, now known as Sierra Oncology, is a clinical stage drug development company in Vancouver that focuses on cancer and hematology treatments. Founded 2004 in Vancouver, British Columbia, Canada by Mina Patel Sooch and Robert Forgey, Sierra Oncology has a pipeline of novel therapies that target the DNA Damage Response (DDR) network. Its lead drug candidate, Momelotinib, is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a targeted mechanism of action that enables it to address all three key drivers of myelofibrosis. Momelotinib’s differentiated therapeutic profile encompasses robust constitutional symptom improvements, a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, and comparable spleen control to ruxolitinib. More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis. Sierra has also launched the MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor. The U.S. Food and Drug Administration has granted Fast Track designation to momelotinib. Momelotinib is protected by patents anticipated to provide potential exclusivity to 2040 in the United States and Europe (including Patent Term Extension or Supplementary Protection Certificate).
Dr. Barbara Klencke
Chief Development Officer
President & Chief Executive Officer